| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 398 | 2019 |
| Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets S Khan, S Shukla, S Sinha, SM Meeran Cytokine & growth factor reviews 24 (6), 503-513, 2013 | 185 | 2013 |
| Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity Y He, X Zhang, J Chang, HN Kim, P Zhang, Y Wang, S Khan, X Liu, ... Nature communications 11 (1), 1996, 2020 | 180 | 2020 |
| PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics S Khan, Y He, X Zhang, Y Yuan, S Pu, Q Kong, G Zheng, D Zhou Oncogene 39 (26), 4909-4924, 2020 | 163 | 2020 |
| Synthesis of β-Carboline-Based N-Heterocyclic Carbenes and Their Antiproliferative and Antimetastatic Activities against Human Breast Cancer Cells SU Dighe, S Khan, I Soni, P Jain, S Shukla, R Yadav, P Sen, SM Meeran, ... Journal of Medicinal Chemistry 58 (8), 3485-3499, 2015 | 108 | 2015 |
| DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ... Journal of hematology & oncology 13, 1-13, 2020 | 75 | 2020 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 73 | 2021 |
| Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies Y He, S Khan, Z Huo, D Lv, X Zhang, X Liu, Y Yuan, R Hromas, M Xu, ... Journal of hematology & oncology 13, 1-24, 2020 | 73 | 2020 |
| Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity X Zhang, D Thummuri, X Liu, W Hu, P Zhang, S Khan, Y Yuan, D Zhou, ... European journal of medicinal chemistry 192, 112186, 2020 | 72 | 2020 |
| Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/β-catenin signaling axis S Shukla, S Sinha, S Khan, S Kumar, K Singh, K Mitra, R Maurya, ... Scientific reports 6 (1), 21860, 2016 | 72 | 2016 |
| Cucurbitacin B inhibits breast cancer metastasis and angiogenesis through VEGF-mediated suppression of FAK/MMP-9 signaling axis S Sinha, S Khan, S Shukla, AD Lakra, S Kumar, G Das, R Maurya, ... The international journal of biochemistry & cell biology 77, 41-56, 2016 | 65 | 2016 |
| Centchroman suppresses breast cancer metastasis by reversing epithelial–mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling S Khan, S Shukla, S Sinha, AD Lakra, HK Bora, SM Meeran The International Journal of Biochemistry & Cell Biology 58, 1-16, 2015 | 60 | 2015 |
| Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis S Shukla, S Khan, S Kumar, S Sinha, M Farhan, HK Bora, R Maurya, ... Cancer prevention research 8 (6), 552-562, 2015 | 56 | 2015 |
| Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells S Sinha, S Shukla, S Khan, TO Tollefsbol, SM Meeran Molecular and cellular endocrinology 406, 102-114, 2015 | 50 | 2015 |
| Inhibition of inositol 1, 4, 5‐trisphosphate receptor induce breast cancer cell death through deregulated autophagy and cellular bioenergetics A Singh, M Chagtoo, S Tiwari, N George, B Chakravarti, S Khan, ... Journal of cellular biochemistry 118 (8), 2333-2346, 2017 | 39 | 2017 |
| Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells R Kolb, U De, S Khan, Y Luo, MC Kim, H Yu, C Wu, J Mo, X Zhang, ... Nature communications 12 (1), 1281, 2021 | 36 | 2021 |
| Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216 D Thummuri, S Khan, PW Underwood, P Zhang, J Wiegand, X Zhang, ... Molecular cancer therapeutics 21 (1), 184-192, 2022 | 34 | 2022 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 29 | 2022 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 29 | 2021 |
| Epigenetic targets in cancer and aging: dietary and therapeutic interventions S Khan, S Shukla, S Sinha, SM Meeran Expert opinion on therapeutic targets 20 (6), 689-703, 2016 | 26 | 2016 |
Peiyi ZhangChemist, University of FloridaVerified email at cop.ufl.edu
